Background-Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is a cardiomyopathy characterized by ventricular arrhythmias and an abnormal right ventricle. Implantable cardioverter defibrillator (ICD) therapy may prevent sudden cardiac death in patients with ARVD/C. Currently, an overview of outcomes, appropriate and inappropriate interventions, and complications of ICD therapy in ARVD/C is lacking. Methods and Results-A literature search was performed to identify studies reporting outcome and complications in patients with ARVD/C who underwent ICD implantation. Of 641 articles screened, 24 studies on 18 cohorts were eligible for inclusion. In case of multiple publications on a cohort, the most recent publication was included in the meta-analysis. There were 610 patients (mean age, 40.4 years; 42% women), who had an ICD for primary or secondary prevention of sudden cardiac death. Risk factors for sudden cardiac death were presyncope (61%), syncope (31%), previous cardiac arrest (14%), ventricular tachycardia (58%), and ventricular fibrillation (6%). Antiarrhythmic medication consisted mostly of β-blockers (38%), amiodarone (14%), or sotalol (30%). During the 3.8-year follow-up, annualized cardiac mortality rate was 0.9%, annualized noncardiac mortality rate was 0.8%, and annualized heart transplant rate was 0.9%. The annualized appropriate and inappropriate ICD intervention rates were 9.5% and 3.7%, respectively. ICD-related complications consisted of difficult lead placement (18.4%), lead malfunction (9.8%), infection (1.4%), lead displacement (3.3%), and any complication (20.3%).
A rrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is an inherited cardiomyopathy characterized by ventricular arrhythmias in the setting of structural and functional abnormalities of the right ventricle attributable to segmental or diffuse replacement of myocytes by fatty and fibrous tissue. 1 The diagnosis of ARVD/C is based on a combination of diagnostic criteria proposed by the International Task Force for Cardiomyopathy, and may be challenging in patients with early and mild forms of the disease. 2, 3 Patients with ARVD/C usually present with symptoms that arise from ventricular arrhythmias, such as palpitations, dizziness, chest discomfort, or syncope. Sudden cardiac death (SCD) caused by sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) may be the initial presentation of ARVD/C. 4 Postmortem studies indicate that ARVD/C is an important cause of SCD among young people. 5, 6 Treatment of patients with ARVD/C is aimed at reducing life-threatening ventricular arrhythmias and may include antiarrhythmic medication, catheter ablation, and implantable cardioverter defibrillator (ICD) therapy.
Multiple studies have demonstrated that ICD therapy is an effective safeguard for primary and secondary prevention of SCD in patients with ARVD/C. Still, ICD therapy is not without risk in patients with ARVD/C. The structural changes of the right ventricle may hinder implantation of the ICD leads, and preclude ventricular sensing and pacing. Programming of the ICD may be challenging because these patients may develop supraventricular and ventricular arrhythmias with similar rates. Patients with ARVD/C are often young and are expected to live for long periods with the implanted device and leads. A complete overview of outcomes and complications after ICD therapy in these patients is currently not available. This information is relevant for clinical decision-making and counseling of patients with ARVD/C at risk for SCD. Therefore, the goal of this analysis was to pool the available studies to assess the precise rate of cardiac and noncardiac mortality, appropriate and inappropriate ICD interventions, and complications after ICD therapy in patients with ARVD/C.
Methods

Search Strategy and Study Selection
This systematic review and meta-analysis included all available original studies reporting clinical outcome and complications in patients with ARVD/C who underwent ICD implantation. Studies that did not provide data on outcome or complications and review articles were excluded. Studies focusing on SCD in patients with ARVD/C without ICD were excluded.
The online MEDLINE database was searched for literature in November 2012 using PubMed (National Center for Biotechnology Information, US National Library of Medicine, Bethesda, MD). The search strategy was right ventricular and defibrillator. No time restriction for publication dates was used. All titles and abstracts of the articles were evaluated. After exclusion based on the title and abstract, full articles were evaluated, and articles meeting the inclusion criteria were identified. In addition, a manual search of the reference lists of the identified studies was performed, and references were evaluated using the same inclusion and exclusion criteria.
Data Extraction
Selected studies were reviewed, and relevant patient characteristics, risk factors for SCD, and follow-up duration were registered. ICD characteristics and device programming were registered. Extracted outcome parameters were the following: cardiac mortality, noncardiac mortality, heart transplant, appropriate ICD intervention, inappropriate ICD intervention, and complications, including difficult lead placement, lead malfunction, infection, lead displacement, and any complications. The outcome parameter of any complication included all reported ICD-related complications, except inappropriate ICD intervention; this parameter was registered separately. No time restriction for complications was used; both early and late complications were included in the analysis. Studies with overlapping data were identified and, in cases of apparent serial reporting of a particular patient cohort, only the most recent publication was included in the meta-analysis. However, all serial publications on a particular cohort were registered and tabulated.
Statistical Analysis
Statistical analysis was performed using Microsoft Excel 2010 (Microsoft Corporation, Redmond, WA) and SPSS version 15.0 (SPSS Inc, Chicago, IL). Continuous variables were reported as mean. Categorical variables were summarized as percentages. Heterogeneity among the studies was assessed using the Q test and I 2 index. Fixed effects model was used to calculate summary estimates of the outcome data. From the pooled data, summary estimates of patient characteristics and risk factors for SCD were calculated. Meta-analysis of the outcome data was performed, and sample size weighted event rates and sample size weighted annualized event rates were calculated. The follow-up duration was weighted for sample size. Forest plots were constructed to present data on appropriate and inappropriate ICD interventions. 31
Results
Search Results
As outlined in Figure 1 , the search strategy identified 641 articles. After review, exclusion, and cross-referencing, a total of 24 studies were included in the systematic review (Table 1) . Overall, 18 different patient cohorts could be identified in these 24 studies. Because of apparent serial reporting of patient cohorts, 6 duplicate studies 7, 11, [13] [14] [15] [16] were not considered for the meta-analysis. The remaining 18 studies [8] [9] [10] 12, [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] were included in the quantitative synthesis (meta-analysis). The summary estimates of patients' outcomes, appropriate and inappropriate interventions, and complications are based on these 18 studies. Heterogeneity among these 18 studies, as assessed using the Q test and I 2 index, was low. Two of the 18 studies in the meta-analysis included only patients with ARVD/C who received an ICD for primary prevention of SCD. 27, 29 Corrado et al 12 studied the role of ICD therapy in patients with ARVD/C and no previous VF or sustained VT. Two studies reported on a population of patients with ARVD/C with a specific genotype, respectively, a high-risk DNA haplotype, 18 and a phospholamban R14del mutation. 30
Patient Characteristics
In total, the analysis included 610 patients (mean age, 40.4 years; 42% women), who had received an ICD for primary or secondary prevention of SCD. Risk factors for SCD were presyncope (61%), syncope (31%), previous cardiac arrest (14%), VT (58%), or VF (6%). An overview of antiarrhythmic medication is provided in Table I in the online-only Data Supplement. Antiarrhythmic medication consisted mostly of β-blockers (38%), amiodarone (14%), or sotalol (30%).
ICD Characteristics and Programming
Information on the use of single-chamber or dual-chamber devices was available in 7 (39%) studies, including 330 patients ( Table II in of the patients received a single-chamber ICD (63%), whereas 37% had a dual-chamber ICD. Four (22%) studies provided information on programming of arrhythmia detection criteria and ICD interventions. In 3 of these studies, 10, 12, 21 no uniformly adapted ICD programming protocol was used, and programming was left at discretion of the treating physician. The mean cycle lengths of the programmed VT and VF detection windows are summarized in Table II in the online-only Data Supplement. In the study by Santangeli et al, 29 the ICDs were uniformly programmed in all patients, however, no details were provided.
ICD Interventions and Outcome
During the mean 3.8-year follow-up, 233 patients had an appropriate ICD intervention, and 75 patients had an inappropriate ICD intervention ( Table 2 ). The annualized appropriate ICD intervention rate was 9.5%, and the annualized inappropriate ICD intervention rate was 3.7% (Figures 2 and 3) . Mortality data were reported in 14 (78%) studies; there were 7 (1%) cardiac deaths and 8 (2%) noncardiac deaths (Table III in the online-only Data  Supplement) . The annualized cardiac mortality rate was 0.9%, and the annualized noncardiac mortality rate was 0.8%. Five (28%) studies provided information on the incidence of heart transplantation during follow-up, occurring in 8 of 133 (6%) patients. The annualized heart transplant rate was 0.9%.
Adverse Effects
Eight (44%) studies, including 283 patients, provided information on ICD-related complications. Difficult ICD lead placement was a frequently occurring complication (18.4%). Other ICD-related 
Discussion
This meta-analysis demonstrates a low incidence of cardiac and noncardiac mortality after ICD implantation in patients with ARVD/C. Appropriate ICD interventions occur at a rate of 9.5%/y. Of note, the relatively high rate of appropriate ICD interventions occurs despite a substantial proportion of the patient population using antiarrhythmic medication. Clearly, appropriate ICD intervention is not synonymous with prevention of SCD, as ventricular arrhythmias may terminate spontaneously or by medical intervention. The survival benefit of ICD therapy in patients with ARVD/C could not be assessed in this analysis.
The current ACC/AHA/ESC (American College of Cardiology/American Heart Association/European Society of Cardiology) guidelines 32 recommend ICD implantation for the prevention of SCD in patients with ARVD/C with documented sustained VT or VF who are receiving optimal medical therapy and have a reasonable expectation of survival (Class I recommendation). In the studies of the current pooled analysis, the decision strategy for ICD implantation for secondary prevention of SCD was comparable with the recommendation in the guidelines. For primary prevention of SCD in patients with ARVD/C, the guidelines state that ICD implantation can be effective (Class IIa recommendation) for the prevention of SCD in patients with extensive disease, including those with left ventricular involvement, ≥1 affected family member with SCD, or undiagnosed syncope when VT or VF has not been excluded as the cause of syncope, who are receiving optimal medical therapy and have a reasonable expectation of survival. In the majority of the studies in the present analysis, clear information on the decision strategy before ICD implantation for primary prevention of SCD was not available. Nevertheless, the population in the pooled analysis was at increased risk of SCD, because 61% had experienced a presyncope, 31% had syncope, and 58% had a documented VT. The risk of SCD was confirmed during the 3.8-year follow-up, by the annualized appropriate ICD intervention rate of 9.5%.
This meta-analysis demonstrates that ICD therapy in patients with ARVD/C may lead to considerable morbidity. Inappropriate ICD intervention and complications occurred at a rate of 3.7%/y and 4.4%/y, respectively. Patients with ARVD/C may be more prone to inappropriate ICD therapy because of the young age at implantation (the mean age of the patients was 40.4 years). Additionally, patients with ARVD/C may develop supraventricular arrhythmias, which may trigger inappropriate ICD intervention. Difficult lead placement was a frequently reported complication, occurring in 18.4% of the patients. The structural and functional abnormalities of the right ventricle in patients with ARVD/C may hinder proper sensing and pacing, and require repeated testing of the right ventricular lead. There is a relation between the extent of right ventricular involvement revealed by angiography or endomyocardial biopsy and the need for testing of the right ventricular lead in ≥2 positions. 7 The inappropriate ICD interventions and ICD-related complications are a significant source of morbidity. Patients with ARVD/C are often otherwise healthy and young individuals, and the management of ICD-related adverse events may be challenging and has a negative impact on their quality of life. 33, 34 Obviously, the indication, benefits, and risks associated with ICD therapy should be carefully considered and discussed with the patient during the decisionmaking process before ICD implantation. This is particularly relevant for patients with ARVD/C because most of them will live for long periods with the implanted device and leads. The value of ICD therapy not only depends on selection of patients and careful implantation and follow-up, but also on programming of the device. Strategic programming of arrhythmia detection criteria and ICD intervention reduces the number of inappropriate interventions without compromising safety. The MADIT-RIT (Multicenter Automatic Defibrillator Implantation Trial: Reduce Inappropriate Therapy) trial 35 randomly assigned 1500 patients with ischemic or nonischemic heart disease and a primary prevention indication to receive an ICD with 1 of 3 programming configurations. During a 1.4year follow-up, high-rate therapy and delayed ICD therapy, as compared with conventional device programming, led to a reduction of inappropriate ICD interventions and a reduction of all-cause mortality. This meta-analysis demonstrates that in 3 of 4 studies, device programming was left at discretion of the treating physician, and specific programming approaches were not evaluated systematically. Strategic device programming may also reduce inappropriate ICD interventions and increase survival among patients with ARVD/C.
Novel developments in ICD technology may further improve outcome and decrease the risk of adverse events in patients with ARVD/C. The entirely subcutaneous ICD eliminates the need for lead placement in or on the heart. Recently, Olde Nordkamp et al 36 studied the outcome and complications of the entirely subcutaneous ICD in 118 patients, most of whom (38%) had an ischemic cardiomyopathy. During a 1.5-year follow-up, the annualized inappropriate ICD intervention rate was 8.7%, and the annualized complication rate was 9.3%. The relatively high rate of ICD-related adverse events was, according to the authors, related to the limited experience with implantation and follow-up of this novel device. At the present time, the entirely subcutaneous ICD does not result in better outcomes and does not decrease the number of ICD-related adverse events, as compared with the established device and lead technology.
Limitations
This meta-analysis has some limitations. The data were extracted from observational studies, and the quantitative synthesis of the data may have resulted in pooling of patients with different clinical characteristics and different risk profiles for SCD. It was assumed that missing (not reported) data were missing at random that was not testable. ARVD/C is a relatively infrequent disease, and most of the studies were performed in tertiary referral centers. This may have resulted in publication bias. Additionally, there is a selection bias in the available studies. The patients who received an ICD were considered to be at increased risk of SCD. There were likely patients who had a perceived low risk and did not receive an ICD and are not captured in this data. Not all studies provided unequivocal information on the number of patients that received an ICD for primary prevention or secondary prevention of SCD. The guidelines state that primary prevention is for those who are at risk but have not yet had a life-threatening ventricular arrhythmia or SCD episode, or secondary for those patients who have already experienced such arrhythmias or events. 33 Table 1 demonstrates that in the study of Corrado et al, 12 previous syncope was reported in 40% of the patients with no previous VF or sustained VT. In the study of Santangeli et al 29 that focused on patients with an ICD for primary prevention of SCD, 34% had a previous syncope. Probably a subset of these patients had a syncope secondary to a nondocumented life-threatening VT. Finally, the majority of the studies did not provide clear information on the decision strategy for primary prevention of SCD. The challenge for the future will be to develop reliable risk stratification strategies for primary prevention of SCD in patients with ARVD/C.
Conclusions
Cardiac and noncardiac mortality rates after ICD implantation in patients with ARVD/C are low. Appropriate ICD interventions occur at a rate of 9.5%/y. Inappropriate ICD interventions and complications lead to considerable ICD-related morbidity.
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